1. Antibody-drug Conjugate/ADC Related
  2. Antibody-Drug Conjugates (ADCs)
  3. Lorvotuzumab mertansine

Lorvotuzumab mertansine  (Synonyms: IMGN-901; BB-1090)

Art. -Nr.: HY-132262 Reinheit: 99.44%
Handling Instructions Technical Support

Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Lorvotuzumab mertansine

Lorvotuzumab mertansine Chemische Struktur

CAS. Nr. : 1008106-64-6

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 Customer Validation

Top Publications Citing Use of Products
  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1].

In Vitro

Lorvotuzumab mertansine (0.001-100 nM, 8 days) shows targeted cell killing activity against both cell lines, with the IC50 values of 0.2 nM for NCI-H526 and 5 nM for NCI-H69 cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lorvotuzumab mertansine (3-51 mg/kg, i.v., once) has potent anti-tumour activity in CB.17 SCID mice with SW2 SCLC xenograft tumor[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SW2 SCLC xenograft tumor CB.17 SCID mice
Dosage: 3、17 and 51 mg/kg
Administration: i.v., once
Result: Showed high anti-tumor activity at a dose of 17 mg/kg with half of the animals being tumor free and complete tumor regression at a dose of 51 mg/kg.
Klinische Studie
CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Lorvotuzumab mertansine]

Versand

Shipping with dry ice.

Speicherung

-80°C, protect from light

Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

 

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

     

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Lorvotuzumab mertansine
Art. -Nr.:
HY-132262
Menge:
MCE Japan Authorized Agent: